PROCYSBI Receives FDA Approval in the U.S.

CCIR is pleased to share with you breaking news from Raptor Pharmaceutical regarding U.S. FDA approval of the drug PROCYSBI. This is a delayed release formulation of cysteamine bitratrate for the treatment of cystinosis. The drug is prescribed for administration every 12 hours compared to every 6 hours for Cystagon. Please follow either of the links below to read more.
Raptor Press Release
MarketWatch PROCYSBI story